Translate page

To help physicians confidently treat people with CML during the pandemic, the iCMLf has collected and analysed COVID-19 cases among patients with CML globally.

With over 1,000 cases reported by >190 physicians from 59 countries the iCMLf CANDID study represents the largest cohort of CML patients with COVID-19 aiming to collect and analyse characteristics of COVID-19 cases among CML patients globally.


An analysis based on 642 cases looking at various risk factors for clinical outcomewas presented at the American Society of Hematology (ASH) Meeting in December 2021 and a publication of the final data is expected early next year.

CANDID presentation ASH During ASH, Dr Katia Pagnano presented an update of the CANDID data that explored the impact of various risk factors, such as co-morbidities, age, disease phase, CML treatment and economic status of the country of origin on clinical outcomes.

An update of the CANDID study -
Poor outcomes for patients with comorbidities, older age, advanced phase disease, and those from low-income countries

'The mortality rate of COVID-19 in CML was lower than in other haematological diseases’ (Dr Katia Pagnano)

The analysis based on 642 cases of COVID-19 reported from 49 countries confirmed a higher mortality for CML patients with COVID-19 in older patients (>75 years), patients with cardiovascular or pulmonary comorbidities and from low and low-middle income countries, the latter probably related to limitations in supportive care. Additionally, more deaths occurred in patients in advanced phases and in patients not in MMR.

CML treatment and line of TKI therapy did not influence the COVID-19 outcome.

Read the full abstract here

Final CML and COVID-19 case summary
Since the ASH abstract was submitted we have closed the registry and are now working on the final data. 

The full case summary comprises a total case number of 1,056 COVID-19 and CML cases submitted from 157 institutions in 59 countries. 418 cases reported on COVID-19 vaccination and the impact of vaccination will be analysed in the follow-up.  

We are looking forward to sharing the full statistical analysis with you soon.